Elsevier

The Lancet

Volume 374, Issue 9700, 31 October–6 November 2009, Pages 1484-1485
The Lancet

Comment
Second primary cancers in survivors of childhood cancer

https://doi.org/10.1016/S0140-6736(09)61885-7Get rights and content

References (16)

  • JH Olsen et al.

    Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries

    J Natl Cancer Inst

    (2009)
  • JP Neglia et al.

    Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study

    J Natl Cancer Inst

    (2001)
  • HC Jenkinson et al.

    Long-term population-based risks of second malignant neoplasms after childhood cancer in Britain

    Br J Cancer

    (2004)
  • S Bhatia et al.

    Second cancers in survivors of childhood cancer

    Nat Rev Cancer

    (2002)
  • WE Evans et al.

    Pharmacogenomics—drug disposition, drug targets, and side effects

    N Engl J Med

    (2003)
  • M Berwick et al.

    Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review

    J Natl Cancer Inst

    (2000)
  • AC Mertens et al.

    Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study

    J Natl Cancer Inst

    (2008)
  • KC Oeffinger et al.

    Chronic health conditions in adult survivors of childhood cancer

    N Engl J Med

    (2006)
There are more references available in the full text version of this article.

Cited by (33)

  • Cancer screening in the pediatric cancer patient: a focus on genitourinary malignancies, and why does a urologist need to know about this?

    2019, Journal of Pediatric Urology
    Citation Excerpt :

    The reasons for non-compliance are predominantly focused on five major points. They are inadequate education of the patient, inadequate education of the physician, insufficient interphysician communication, the patient's fiscal constraints, and the decreased cognition of the patient that may develop as a consequence of chemoradiation therapy [9,11,13,14,18]. The purpose of this article is the education of the physician to recognize the high-risk patient who should be recommended for follow-up for cancer surveillance.

  • GH deficiency in adult survivors of childhood cancer

    2016, Best Practice and Research: Clinical Endocrinology and Metabolism
    Citation Excerpt :

    In CCS treated with GH, the first concern regards the increased risk of disease recurrence. The second one is the supposed effect of GH administration on the development of SNs, which represents one of the most feared late complication of anticancer treatments [46–48]. In the 2000s Swerdlow et al. evaluated 180 CCS with brain tumor treated with GH between 1965 and 1996.

  • Access to preventive health care for cancer survivors

    2013, American Journal of Preventive Medicine
View all citing articles on Scopus
View full text